Current Report Filing (8-k)
08 September 2020 - 9:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 8, 2020
Protara Therapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-36694
|
|
20-4580525
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
1 Little West 12th Street
New York, NY
|
|
10014
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (646) 844-0337
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
TARA
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On September 8, 2020, Protara Therapeutics, Inc. (the “Company”)
issued a press release entitled “Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting
Advancement in Oncology and Rare Disease Indications,” a copy of which is attached hereto as Exhibit 99.1 to this Current
Report on Form 8-K.
The information in this Item 7.01, including Exhibit 99.1,
is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18
of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall the information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether
made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.
Item 8.01 Other Events.
On September 8, 2020, the Company made available a Corporate
Presentation on the Investor Relations page of the Company’s website, which will be used at investor and other meetings.
A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated
herein by reference. The Company does not undertake to update this presentation.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Protara Therapeutics, Inc.
|
|
|
|
Dated: September 8, 2020
|
By:
|
/s/ Blaine Davis
|
|
|
Blaine Davis
|
|
|
Chief Financial Officer
|
2
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Apr 2024 to May 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From May 2023 to May 2024